Therapeutics for COVID-19 and post COVID-19 complications: An update.
Therapeutics for COVID-19 and post COVID-19 complications: An update.
复制标题
DOI：
10.1016/j.crphar.2022.100086
复制
发表时间：
2022
影响因子：
--
通讯作者：
Mehta AA
中科院分区：
文献类型：
--
作者：
Basu D;Chavda VP;Mehta AA
自2020年12月下旬在中国爆发以来，新型冠状病毒影响了全球社会经济。目前，全世界正在寻求针对COVID-19的安全有效的治疗措施以根除它。作为药物再利用的一部分，许多已建立的药物分子都针对 SARS-CoV-2 进行了测试，其中一些被证明可以有效缓解症状，而另一些则无效。药物再利用是快速开发抗病毒药物的实用策略。目前，许多药物正在利用对疾病发病机制和药物药效学的基本了解以及计算方法进行重新利用。在目前情况下，药物再利用可以被视为 COVID-19 的新治疗选择。几种针对 SARS-CoV-2 的新药物分子和生物制剂正处于不同的临床开发阶段。美国食品药品监督管理局批准了一些生物制剂产品紧急用于新冠病毒管理。由于持续突变，许多已批准的疫苗无法有效地使个体对 SARS-CoV-2 突变体的机会性感染产生免疫。因此，迫切需要有效的治疗剂来管理新冠病毒。在这篇综述中，对 SARS-CoV-2 的治疗进展进行了综合总结，并对 COVID-19 后并发症的有效管理进行了概述。随着 SARS-CoV-2 的持续突变，迫切需要有效的治疗剂来管理新冠病毒。迄今为止，用于对抗 COVID-19 的重新利用药物的有效性尚不明显。文章总结了美国 FDA 批准的治疗 COVID-19 的药物清单。几种新的药物分子和生物制剂是针对 SARS-CoV-2 设计的。描述了针对 SARS-CoV-2 的治疗进展的综合总结，以及对 COVID-19 后并发症的有效管理的概述。
Since its inception in late December 2020 in China, novel coronavirus has affected the global socio-economic aspect. Currently, the world is seeking safe and effective treatment measures against COVID-19 to eradicate it. Many established drug molecules are tested against SARS-CoV-2 as a part of drug repurposing where some are proved effective for symptomatic relief while some are ineffective. Drug repurposing is a practical strategy for rapidly developing antiviral agents. Many drugs are presently being repurposed utilizing basic understanding of disease pathogenesis and drug pharmacodynamics, as well as computational methods. In the present situation, drug repurposing could be viewed as a new treatment option for COVID-19. Several new drug molecules and biologics are engineered against SARS-CoV-2 and are under different stages of clinical development. A few biologics drug products are approved by USFDA for emergency use in the covid management. Due to continuous mutation, many of the approved vaccines are not much efficacious to render the individual immune against opportunistic infection of SARS-CoV-2 mutants. Hence, there is a strong need for the cogent therapeutic agent for covid management. In this review, a consolidated summary of the therapeutic developments against SARS-CoV-2 are depicted along with an overview of effective management of post COVID-19 complications. With continuous mutation of SARS-CoV-2, there is a strong need for the potent therapeutic agent for covid management. Effectiveness of repurposed drugs used against COVID-19 till now it's not evident. List of US-FDA approved drugs for COVID-19 were summarized in the article. Several new drug molecules and biologics are engineered against SARS-CoV-2. A consolidated summary of the therapeutic development against SARS-CoV-2 is depicted along with an overview of effective management of postCOVID-19 complications.